Loading...
RSS feeds allow Web site content to be gathered via feed reader software. Click the subscribe link to obtain the feed URL for this page. The feed will update when new content appears on this page.
Sort By: Relevancy | Date | Type
Displaying items 25-36 of 151
» View wsbt.com items only
    May 3, 2013 |Story| Reuters
  1. Big drugmakers think small with nanomedicine deals

    Reuters
    * Nanomedicine promises greater precision and monitoring * Pfizer, Amgen, AstraZeneca among firms placing bets * Early-stage research but scientists see momentum building By Ben Hirschler LONDON, May 3 (Reuters) - Is nanomedicine the next big thing? A...

    Tags: Chemical Industry, Colleges and Universities, AIDS, Massachusetts Institute of Technology, Biotechnology Industry

  2. May 2, 2013 |Story| Reuters
  3. Deals of the day -- mergers and acquisitions

    Reuters
    May 2 (Reuters) - The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Thursday: ** New York-based private equity firm Lightyear Capital has emerged as the lead bidder to buy SunTrust Banks Inc's RidgeWorth Investments...

    Tags: Companies and Corporations, Mergers, Acquisitions and Takeovers, Politics, France Telecom, Norway

  4. May 9, 2013 |Story| Reuters
  5. PRESS DIGEST-New York Times business news - May 10

    Reuters
    May 10 (Reuters) - The following are the top stories on the New York Times business pages. Reuters has not verified these stories and does not vouch for their accuracy. * The Bank of Japan's efforts to reinvigorate the nation's economy are showing...

    Tags: The New York Times, Viral Diseases and Infections, Human papillomavirus, Merck & Company Incorporated, Kennedy Airport

  6. May 9, 2013 |Story| Reuters
  7. Merck, Glaxo reducen precio de vacuna contra cáncer cervical para países pobres

    Reuters
    LONDRES (Reuters) - Las farmacéuticas Merck y GlaxoSmithKline redujeron el precio de las vacunas contra el cáncer de cuello de útero en un acuerdo que les permitirá venderlas a los países más pobres por menos de 5 dólares la dosis. El nuevo precio...

    Tags: Viral Diseases and Infections, HPV Vaccine, Merck & Company Incorporated

  8. May 9, 2013 |Story| Reuters
  9. European shares dip from multi-year highs

    Reuters
    PARIS, May 9 (Reuters) - European shares fell in early trade on Thursday, halting a sharp three-week rally to multi-year highs, with pharmaceutical stocks trimming recent lofty gains. GlaxoSmithKline and AstraZeneca were both down 0.5 percent. The sector...

    Tags: AstraZeneca Plc

  10. May 9, 2013 |Story| Reuters
  11. Merck, GSK cut price of cervical cancer shots for poor countries

    Reuters
    * Shots will cost less than $5 per dose through GAVI deal * Human papillomavirus causes most cervical cancers * Disease kills 275,000 women a year worldwide * Vaccine group deal aims to protect 30 million girls By Kate Kelland LONDON, May 9 (Reuters)...

    Tags: Chemical Industry, Vaccines, HPV Vaccine, Human papillomavirus, Merck & Company Incorporated

  12. May 8, 2013 |Story| Reuters
  13. REUTERS SUMMIT-Drugmakers split as demands for open data mount

    Reuters
    (For other news from Reuters Health Summit, click on http://www.reuters.com/summit/Health13) * Growing demands for transparency of clinical trial data * Wider disclosure by EU regulator angers drugmakers * GlaxoSmithKline sets up online system for data...

    Tags: Science and Technology, Chemical Industry, Merck & Company Incorporated, Politics, Denmark

  14. May 2, 2013 |Story| Reuters
  15. JP Morgan, Greenhill advising GSK on sale of soft drinks brands

    Reuters
    LONDON, May 2 (Reuters) - JP Morgan and Greenhill have been appointed to advise GlaxoSmithKline on the sale of its soft drinks brands Lucozade and Ribena, which analysts believe will fetch more than 1 billion pounds ($1.6 billion). A spokesman for...

    Tags: Bain Capital, LLC, Lion Capital Holdings, United Kingdom, Japan, Deutsche Bank AG

  16. May 7, 2013 |Story| Reuters
  17. REUTERS SUMMIT-Drug industry CEOs plotting more carve-outs

    Reuters
    (For other news from Reuters Health Summit, click on http://www.reuters.com/summit/Health13) * New generation of CEOs more open to restructuring * Established drug products in focus at Pfizer, GSK, Sanofi * Bankers see divestments helping to unlock...

    Tags: Companies and Corporations, Corporate Officers, Abbott Laboratories, Bain Capital, LLC, Economy, Business and Finance

  18. May 6, 2013 |Story| Reuters
  19. FACTBOX-Vaccine, drugs to fight new bird flu

    Reuters
    (For other news from Reuters Health Summit, click on http://www.reuters.com/summit/Health13) May 6 (Reuters) - The U.N. World Health Organization and the U.S. Centers for Disease Control and Prevention are already working with samples of the new H7N9...

    Tags: Chemical Industry, Tamiflu (drug), Vaccines, Wildlife, AstraZeneca Plc

  20. Apr 22, 2013 |Story| Reuters
  21. GSK to partner with venture capital firm for drug discovery

    Reuters
    April 22 (Reuters) - GlaxoSmithKline said on Monday it will partner with venture capitalists Avalon Ventures in a deal worth up to $495 million to fund as many as 10 drug-discovery startup companies over the next three years. GSK will provide financing...

    Tags: Avalon Ventures Limited, Startups

  22. Apr 21, 2013 |Story| Chicago Tribune
  23. Athletes only too happy to be 'lab rats'

    After discovering that a promising new drug caused multiple types of cancer in lab animals, the pharmaceutical company GlaxoSmithKline stopped developing the compound.
    After discovering that a promising new drug caused multiple types of cancer in lab animals, the pharmaceutical company GlaxoSmithKline stopped developing the compound. But the failed experimental drug, called GW501516, is making a comeback in another...

    Tags: Chemical Industry, Drug Use, Lawyers, Justice System, Bodybuilding

< Previous1 2  3  4 5 6 7 8 9 10 11-13Next >
Original site for GlaxoSmithKline PLC topic gallery.
Loading...
 
 

Date:

Credit:

User-submitted

Tags:

Rate:
Sending...

E-mail this photo

Error: malformed email address(es)
Both "from" and "recipient" email fields are required.

Recipient E-mail Addresses

(up to 3, separated by commas) Send me a copy.

From:

e-mail | buy this photo | link to photo
GlaxoSmithKline PLC Photos
Dr. Jeffrey Bloss has joined Astellas US LLC as vice pr...
(November 28, 2012)
Dr. Jeffrey Bloss, vice president of scientific and medical affairs, Astellas US LLC
Third grader Kira Lingle of Quakertown rolls up a strea...
(July 10, 2012)
Science in the Summer program
CEO of GlaxoSmithKline, Andrew Witty, poses for photogr...
(July 2, 2012)
CEO Andrew Witty